ACM
URGN icon

ADAR1 Capital Management’s UroGen Pharma URGN Stock Holding History

ADAR1 Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$937K – 340
2025
Q4 		$937K Hold
40,000
– – 0.07% 136
2025
Q3 		$798K Buy
+40,000
New +$718K 0.08% 110

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

ADAR1 Capital Management's URGN Position: Q1 2026 in Review

ADAR1 Capital Management increased its UroGen Pharma (URGN) stake by 215% in Q1 2026, buying an estimated $5.41M and bringing the position to 395,459 shares worth $7.11M. The position accounts for 0.42% of the portfolio, ranked #58.

ADAR1 Capital Management first reported a position in URGN in Q2 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • ADAR1 Capital Management held 395,459 shares of UroGen Pharma worth $7.11M as of Q1 2026.
  • ADAR1 Capital Management bought 270,084 UroGen Pharma shares in Q1 2026, an estimated $5.41M.
  • UroGen Pharma made up 0.42% of ADAR1 Capital Management's portfolio in Q1 2026, its #58 holding.
  • ADAR1 Capital Management first reported a position in UroGen Pharma in Q2 2025 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.